EAU 2013 - Programme Book - YouMed

12.05 - 13.00 Clinical forum: Diagnosis and treatment of small foci of PCa
Moderator: M. Brausi, Modena (IT)
12.05 - 12.20 New tools for diagnosis
G. Villeirs, Ghent (BE)
12.20 - 12.35 Pathologic characteristics of low risk PCa: Multifocality and prognostic factors
R. Montironi, Torrette Di Ancona (IT)
12.35 - 12.50 Treatments of low risk PCa
B. Djavan, Vienna (AT)
12.50 - 13.00 Discussion
13.00 - 14.00 Clinical forum: Locally advanced renal cancer
Moderator: A. Lopez-Beltran, Cordoba (ES)
13.00 - 13.15 The role of biopsy in renal masses
A. Volpe, Novara (IT)
13.15 - 13.30 Pathological prognostic factors
F. Algaba, Barcelona (ES)
13.30 - 13.45 Treatment of small renal masses
H.A. Özen, Ankara (TR)
13.45 - 13.55 Discussion
13.55 - 14.00 Close
M. Brausi, Modena (IT)
A. Lopez-Beltran, Cordoba (ES)
Aims and objectives
EORTC GUCG and ESUR:
Clinical trials should be based on targeting molecules which are overexpressed in a disease and functionally
associated with its development and progression. In several human cancers, expression of target candidates
is specific in individual patient tissues and not the same in primary lesions and metastases of one patient.
The purpose of the joint session is to convince the audience that biologically-based clinical trials should
be carried out. Results obtained with experimental models open the ways to use novel agents in cancer
therapy, however there should be an appropriate information about expression of possible targets and
related signaling pathways in clinical specimens available. In addition, new trial methodologies will have to
be developed to clinically assess the response of the cancer to these drugs. This will be done by embedding
traditional endpoints, such as progression free survival and overall survival, with modern functional imaging
endpoints.
EAU Milan 2013
109
Saturday